18457324|t|Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
18457324|a|BACKGROUND: Exposure to anthracyclines as part of cancer therapy has been associated with the development of congestive heart failure (CHF). The potential role of genetic risk factors in anthracycline-related CHF remains to be defined. Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene CBR3) had an impact on the risk of anthracycline-related CHF. METHODS: A nested case-control study was conducted within a cohort of 1979 patients enrolled in the Childhood Cancer Survivor Study who received treatment with anthracyclines and had available DNA. Thirty patients with CHF (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [V244M]). Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 M244) and the anthracycline substrate doxorubicin were used to investigate the functional impact of the CBR3 V244M polymorphism. RESULTS: Multivariate analyses adjusted for sex and primary disease recurrence were used to test for associations between the candidate genetic polymorphisms (NQO1*2 and CBR3 V244M) and the risk of CHF. Analyses indicated no association between the NQO1*2 polymorphism and the risk of anthracycline-related CHF (odds ratio [OR], 1.04; P=.97). There was a trend toward an association between the CBR3 V244M polymorphism and the risk of CHF (OR, 8.16; P=.056 for G/G vs A/A; OR, 5.44; P=.092 for G/A vs A/A). In line, recombinant CBR3 V244 (G allele) synthesized 2.6-fold more cardiotoxic doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01). CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of anthracycline-related CHF among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic anthracycline alcohol metabolites. Larger confirmatory case-control studies are warranted.
18457324	29	49	carbonyl reductase 3	GeneOrGeneProduct	874
18457324	55	59	CBR3	GeneOrGeneProduct	874
18457324	68	100	NAD(P)H:quinone oxidoreductase 1	GeneOrGeneProduct	1728
18457324	106	110	NQO1	GeneOrGeneProduct	1728
18457324	114	122	patients	OrganismTaxon	9606
18457324	137	150	anthracycline	ChemicalEntity	D018943
18457324	159	183	congestive heart failure	DiseaseOrPhenotypicFeature	D006333
18457324	200	206	cancer	DiseaseOrPhenotypicFeature	D009369
18457324	232	246	anthracyclines	ChemicalEntity	D018943
18457324	258	264	cancer	DiseaseOrPhenotypicFeature	D009369
18457324	317	341	congestive heart failure	DiseaseOrPhenotypicFeature	D006333
18457324	343	346	CHF	DiseaseOrPhenotypicFeature	D006333
18457324	395	408	anthracycline	ChemicalEntity	D018943
18457324	417	420	CHF	DiseaseOrPhenotypicFeature	D006333
18457324	570	584	anthracyclines	ChemicalEntity	D018943
18457324	605	673	nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1	GeneOrGeneProduct	1728
18457324	679	683	NQO1	GeneOrGeneProduct	1728
18457324	692	712	carbonyl reductase 3	GeneOrGeneProduct	874
18457324	718	722	CBR3	GeneOrGeneProduct	874
18457324	753	766	anthracycline	ChemicalEntity	D018943
18457324	775	778	CHF	DiseaseOrPhenotypicFeature	D006333
18457324	855	863	patients	OrganismTaxon	9606
18457324	940	954	anthracyclines	ChemicalEntity	D018943
18457324	985	993	patients	OrganismTaxon	9606
18457324	999	1002	CHF	DiseaseOrPhenotypicFeature	D006333
18457324	1072	1076	NQO1	GeneOrGeneProduct	1728
18457324	1078	1082	NQO1	GeneOrGeneProduct	1728
18457324	1090	1094	CBR3	GeneOrGeneProduct	874
18457324	1100	1104	CBR3	GeneOrGeneProduct	874
18457324	1105	1162	valine [V] to methionine [M] substitution at position 244	SequenceVariant	rs1056892
18457324	1164	1169	V244M	SequenceVariant	rs1056892
18457324	1213	1217	CBR3	GeneOrGeneProduct	874
18457324	1228	1232	CBR3	GeneOrGeneProduct	874
18457324	1233	1237	V244	SequenceVariant	rs1056892
18457324	1242	1246	CBR3	GeneOrGeneProduct	874
18457324	1247	1251	M244	SequenceVariant	rs1056892
18457324	1261	1274	anthracycline	ChemicalEntity	D018943
18457324	1285	1296	doxorubicin	ChemicalEntity	D004317
18457324	1351	1355	CBR3	GeneOrGeneProduct	874
18457324	1356	1361	V244M	SequenceVariant	rs1056892
18457324	1535	1539	NQO1	GeneOrGeneProduct	1728
18457324	1546	1550	CBR3	GeneOrGeneProduct	874
18457324	1551	1556	V244M	SequenceVariant	rs1056892
18457324	1574	1577	CHF	DiseaseOrPhenotypicFeature	D006333
18457324	1625	1629	NQO1	GeneOrGeneProduct	1728
18457324	1661	1674	anthracycline	ChemicalEntity	D018943
18457324	1683	1686	CHF	DiseaseOrPhenotypicFeature	D006333
18457324	1771	1775	CBR3	GeneOrGeneProduct	874
18457324	1776	1781	V244M	SequenceVariant	rs1056892
18457324	1811	1814	CHF	DiseaseOrPhenotypicFeature	D006333
18457324	1904	1908	CBR3	GeneOrGeneProduct	874
18457324	1909	1913	V244	SequenceVariant	rs1056892
18457324	1951	1962	cardiotoxic	DiseaseOrPhenotypicFeature	D066126
18457324	1963	1976	doxorubicinol	ChemicalEntity	C010013
18457324	1999	2003	CBR3	GeneOrGeneProduct	874
18457324	2004	2008	M244	SequenceVariant	rs1056892
18457324	2020	2024	CBR3	GeneOrGeneProduct	874
18457324	2025	2029	V244	SequenceVariant	rs1056892
18457324	2060	2064	CBR3	GeneOrGeneProduct	874
18457324	2065	2069	M244	SequenceVariant	rs1056892
18457324	2134	2138	CBR3	GeneOrGeneProduct	874
18457324	2139	2144	V244M	SequenceVariant	rs1056892
18457324	2192	2205	anthracycline	ChemicalEntity	D018943
18457324	2214	2217	CHF	DiseaseOrPhenotypicFeature	D006333
18457324	2234	2240	cancer	DiseaseOrPhenotypicFeature	D009369
18457324	2295	2306	cardiotoxic	DiseaseOrPhenotypicFeature	D066126
18457324	2307	2328	anthracycline alcohol	ChemicalEntity	D000438,D018943
18457324	Positive_Correlation	D066126	C010013	No
18457324	Positive_Correlation	D000438	D066126	No
18457324	Association	rs1056892	D000438	Novel
18457324	Association	rs1056892	C010013	Novel
18457324	Positive_Correlation	rs1056892	D006333	Novel
18457324	Association	rs1056892	D018943	Novel
18457324	Association	D006333	D000438	Novel
18457324	Negative_Correlation	D018943	D009369	No
18457324	Positive_Correlation	D018943	D066126	No
18457324	Positive_Correlation	D018943	D006333	Novel
18457324	Association	874	D066126	Novel
18457324	Association	874	D000438	Novel
18457324	Association	874	C010013	Novel
18457324	Association	874	D006333	Novel
18457324	Association	874	D018943	Novel